AR016428A1 - Compuestos de 1,3,8-triaza-espiro[4,5]decan-4-ona, un proceso para su preparacion, medicamentos que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de un medicamento - Google Patents
Compuestos de 1,3,8-triaza-espiro[4,5]decan-4-ona, un proceso para su preparacion, medicamentos que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de un medicamentoInfo
- Publication number
- AR016428A1 AR016428A1 ARP980106141A ARP980106141A AR016428A1 AR 016428 A1 AR016428 A1 AR 016428A1 AR P980106141 A ARP980106141 A AR P980106141A AR P980106141 A ARP980106141 A AR P980106141A AR 016428 A1 AR016428 A1 AR 016428A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- alkyl
- phenyl
- compounds
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 102100028646 Nociceptin receptor Human genes 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005037 alkyl phenyl group Chemical group 0.000 abstract 2
- -1 cyanomethyl Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 108010020615 nociceptin receptor Proteins 0.000 abstract 2
- 125000004135 2-norbornyl group Chemical group [H]C1([H])C([H])([H])C2([H])C([H])([H])C1([H])C([H])([H])C2([H])* 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000013200 Stress disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 125000004306 triazinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Color Printing (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona, que comprenden compuestos de la formula general (I) en la que: R1 es hidrogeno, alquilo inferior,halogeno, alcoxi inferior, trifluorometilo, alquil-inferior-fenilo o cicloalquilo C5-7; R2 eshidrogeno , alquilo inferior, fenilo o alquil-inferior-fenilo; R3es hidrogeno, alquilo inferior, bencilo, alquil-inferior-fenilo, alquil-inferior-difenilo, triazinilo, cianometilo, alquil-inferior-piperidinilo, alquil-inferior-naftilo, cicloalquiloC5-7, alqui l-inferior-cicloalquilo C5-7, alquil-inferior-piridinilo, alquil-inferior-morfolinilo, alquil-inferior-dioxalanilo,alquil-inferior-oxazolilo o alquil-inferior-2-oxo-oxazolidinilo, y en el que los sistemas de anillos pueden estarsubstituidos adiciona lmente con alquiloinferior, alcoxi inferior, trifluorometilo o fenilo o -(CH2)nC(O)O-alquilo inferior, -(CH2)nC(O)NH2, -(CH2)nC(O)N-(alquilo inferior)2, -(CH2)nOH o-(CH2)nC(O)NHCH2C6H5; R4 es hidrogeno, alquilo inferior onitrilo; A es un sistema de anillo, que consiste en: (a) cicloalquilo C5-15, que puede encontrarseademás de R4 opcionalmente sustituido con alquilo inferior, trifluorometilo, fenilo, cicloalquilo C5-7, espiro-undecan-alquilo o por 2-norbornilo, o esuno delos grupos de formula (b), formula (c), formula (d), dodecahidroacenaftilen-1-ilo (e), biciclo[6.2.0]-dec-9-ilo (f) y biciclononan-9-ilo (g); y donde R5 y R6son hidrogeno, alquilo inferior, o tomados juntos y con los átomos de C a los queestán unidos forman un anillo fen ilo; R7 es hidrogeno o alquilo inferior; lalínea punteada representa un enlace opcional y n es de 1 a 4; y sales de adicion de ácido de los mismos farmacéuticamente aceptables, un proceso para supreparacion,medicamentos que comprenden dichos derivad os y el uso de dichos derivados para la manufactura de un medicamento. Los compuestos de la presenteinvencion son agonistas y/o antagonistas del receptor de Orfanina FQ (OFQ). En consecuencia serán utilesen el tratamiento de déficits de atencion yps icologicos, especialmente per no limitados a mejoría de los síntomas de trastornos de ansiedad y estrés, depresion, trauma, pérdida de memoria debida a
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97121427 | 1997-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR016428A1 true AR016428A1 (es) | 2001-07-04 |
Family
ID=8227753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106141A AR016428A1 (es) | 1997-12-05 | 1998-12-03 | Compuestos de 1,3,8-triaza-espiro[4,5]decan-4-ona, un proceso para su preparacion, medicamentos que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de un medicamento |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6043366A (es) |
| JP (1) | JP3366868B2 (es) |
| KR (1) | KR19990062800A (es) |
| CN (1) | CN1118467C (es) |
| AR (1) | AR016428A1 (es) |
| AT (1) | ATE212635T1 (es) |
| AU (1) | AU744338B2 (es) |
| BR (1) | BR9805297B1 (es) |
| CA (1) | CA2255171C (es) |
| CO (1) | CO4990965A1 (es) |
| CZ (1) | CZ399698A3 (es) |
| DE (1) | DE69803653T2 (es) |
| DK (1) | DK0921125T3 (es) |
| ES (1) | ES2170446T3 (es) |
| HR (1) | HRP980613A2 (es) |
| HU (1) | HUP9802807A3 (es) |
| ID (1) | ID21413A (es) |
| IL (1) | IL127399A0 (es) |
| MA (1) | MA26573A1 (es) |
| NO (1) | NO312161B1 (es) |
| NZ (1) | NZ333159A (es) |
| PE (1) | PE135299A1 (es) |
| PL (1) | PL330062A1 (es) |
| PT (1) | PT921125E (es) |
| SG (1) | SG71173A1 (es) |
| TR (1) | TR199802520A2 (es) |
| TW (1) | TW408123B (es) |
| YU (1) | YU55198A (es) |
| ZA (1) | ZA9811128B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE289307T1 (de) * | 1998-10-23 | 2005-03-15 | Pfizer | 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten |
| EP1537110B1 (en) * | 1999-12-06 | 2007-01-17 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
| JP4356453B2 (ja) * | 2001-07-23 | 2009-11-04 | 萬有製薬株式会社 | ４−オキソイミダゾリジン−２−スピロピペリジン誘導体 |
| WO2003082333A1 (fr) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remede contre les troubles du sommeil |
| EP1601674B1 (en) * | 2002-09-09 | 2012-08-08 | Janssen Pharmaceutica NV | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| AU2003299791A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| WO2004104004A2 (en) * | 2003-05-23 | 2004-12-02 | Zealand Pharma A/S | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| US20060178390A1 (en) * | 2004-08-02 | 2006-08-10 | Alfonzo Jordan | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| BRPI0609580A2 (pt) * | 2005-03-22 | 2010-04-20 | Hoffmann La Roche | composto, polimorfo cristalino, processo para a sua manufatura, composições farmacêuticas que o contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização do composto |
| CN101472924A (zh) * | 2006-06-20 | 2009-07-01 | 惠氏公司 | Kv1.5钾通道抑制剂 |
| EP2102206B1 (en) * | 2006-11-28 | 2015-04-08 | Janssen Pharmaceutica NV | Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
| WO2008105497A1 (ja) | 2007-03-01 | 2008-09-04 | Mitsubishi Tanabe Pharma Corporation | ベンゾイミダゾール化合物およびその医薬用途 |
| EP2150552B1 (en) * | 2007-04-09 | 2013-01-02 | Janssen Pharmaceutica NV | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| PA8801401A1 (es) * | 2007-10-25 | 2009-05-15 | Janssen Pharmaceutica Nv | Arilindenopirimidinas y su uso como adenosina a2a |
| TW201016675A (en) * | 2008-09-16 | 2010-05-01 | Mitsubishi Tanabe Pharma Corp | Crystalline benzoimidazole compound and salt thereof |
| US20100076003A1 (en) * | 2008-09-19 | 2010-03-25 | Kathleen Battista | 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators |
| WO2010037081A1 (en) * | 2008-09-29 | 2010-04-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific spiro-piperidine compounds |
| EP2443124B1 (en) | 2009-06-16 | 2014-01-22 | Merck Sharp & Dohme Corp. | Substituted -1,3,8-triazaspiro[4.5]decane-2,4-diones |
| JP7002335B2 (ja) * | 2015-07-03 | 2022-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161644A (en) * | 1962-06-22 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-benzyl-4-substituted piperidines |
| US3155670A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3155669A (en) * | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| US3238216A (en) * | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| JPS5212171A (en) * | 1975-07-17 | 1977-01-29 | Yoshitomi Pharmaceut Ind Ltd | Process for preparation of cyclohexane derivatives |
| JPS51100084A (es) * | 1975-02-28 | 1976-09-03 | Yoshitomi Pharmaceutical | |
| GB1486546A (en) * | 1975-02-28 | 1977-09-21 | Yoshitomo Pharma Ind Ltd | 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof |
| JPS5934713B2 (ja) * | 1976-01-05 | 1984-08-24 | ウェルファイド株式会社 | 脂環式誘導体 |
| US4076821A (en) * | 1976-02-27 | 1978-02-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof |
| US4329353A (en) * | 1980-10-22 | 1982-05-11 | Janssen Pharmaceutica, N.V. | 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof |
| MA19091A1 (fr) * | 1980-03-10 | 1981-10-01 | Janssen Pharmaceutica Nv | Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine . |
| GR73633B (es) * | 1980-03-10 | 1984-03-26 | Janssen Pharmaceutica Nv | |
| ATE67769T1 (de) * | 1983-01-25 | 1991-10-15 | Ciba Geigy Ag | Neue peptidderivate. |
| JPS6012357B2 (ja) * | 1984-01-23 | 1985-04-01 | 吉富製薬株式会社 | 脂環式誘導体 |
| CA2226058C (en) * | 1997-01-30 | 2008-01-29 | F. Hoffmann-La Roche Ag | 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives |
-
1998
- 1998-11-27 DK DK98122511T patent/DK0921125T3/da active
- 1998-11-27 ES ES98122511T patent/ES2170446T3/es not_active Expired - Lifetime
- 1998-11-27 DE DE69803653T patent/DE69803653T2/de not_active Expired - Lifetime
- 1998-11-27 AT AT98122511T patent/ATE212635T1/de active
- 1998-11-27 PT PT98122511T patent/PT921125E/pt unknown
- 1998-12-03 CA CA002255171A patent/CA2255171C/en not_active Expired - Fee Related
- 1998-12-03 PE PE1998001176A patent/PE135299A1/es not_active Application Discontinuation
- 1998-12-03 NZ NZ333159A patent/NZ333159A/en unknown
- 1998-12-03 AR ARP980106141A patent/AR016428A1/es active IP Right Grant
- 1998-12-03 US US09/204,184 patent/US6043366A/en not_active Expired - Fee Related
- 1998-12-03 YU YU55198A patent/YU55198A/sh unknown
- 1998-12-03 PL PL98330062A patent/PL330062A1/xx unknown
- 1998-12-03 ID IDP981576A patent/ID21413A/id unknown
- 1998-12-03 SG SG1998005141A patent/SG71173A1/en unknown
- 1998-12-04 HR HR97121427.5A patent/HRP980613A2/hr not_active Application Discontinuation
- 1998-12-04 IL IL12739998A patent/IL127399A0/xx unknown
- 1998-12-04 CO CO98072457A patent/CO4990965A1/es unknown
- 1998-12-04 CZ CZ983996A patent/CZ399698A3/cs unknown
- 1998-12-04 NO NO19985684A patent/NO312161B1/no not_active IP Right Cessation
- 1998-12-04 TR TR1998/02520A patent/TR199802520A2/xx unknown
- 1998-12-04 MA MA25369A patent/MA26573A1/fr unknown
- 1998-12-04 BR BRPI9805297-7A patent/BR9805297B1/pt not_active IP Right Cessation
- 1998-12-04 HU HU9802807A patent/HUP9802807A3/hu unknown
- 1998-12-04 JP JP34527898A patent/JP3366868B2/ja not_active Expired - Fee Related
- 1998-12-04 KR KR1019980053080A patent/KR19990062800A/ko active Search and Examination
- 1998-12-04 AU AU96087/98A patent/AU744338B2/en not_active Ceased
- 1998-12-04 TW TW087120132A patent/TW408123B/zh not_active IP Right Cessation
- 1998-12-04 ZA ZA9811128A patent/ZA9811128B/xx unknown
- 1998-12-04 CN CN98122759A patent/CN1118467C/zh not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016428A1 (es) | Compuestos de 1,3,8-triaza-espiro[4,5]decan-4-ona, un proceso para su preparacion, medicamentos que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de un medicamento | |
| AR038259A1 (es) | Derivados sustituidos de aril-1,4-pirazina, composiciones farmaceuticas que los contienen, su uso para la elaboracion de medicamentos, articulo de fabricacion que los comprende, metodo para inhibir la union del crf al receptor de crf1, metodo para clasificar ligandos de receptores del crf y metodo p | |
| ES2220541T3 (es) | Derivados de bencimidazolinas con afinidad mixta para receptores de serotonina y dopamina. | |
| AR016431A1 (es) | Derivados de piperidina, un proceso para su preparacion, medicamentos que los comprenden y el uso de dichos derivados para la manufactura de un medicamento | |
| AR029760A1 (es) | Derivados de quinuclidina, proceso para preparar dichos derivados, compuestos intermediarios utilizables en dicho proceso, composiciones farmaceuticas formuladas con dichos derivados y uso de dichos derivados para la produccion de medicamentos para el tratamiento de enfermedades respiratorias, urina | |
| PA8559901A1 (es) | Uso de ureas de benzotiazoles | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| AR014313A1 (es) | Derivados de benzosulfona, medicamento que los contiene, procedimiento para su preparacion y su empleo para la manufactura de dicho medicamento | |
| AR007897A1 (es) | Un compuesto derivado de la 4-hidroxi-piperidina, su empleo para la elaboracion de un medicamento, un procedimiento para prepararlo, y un medicamento que lo contiene. | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| IL175572A (en) | Condensed heterocycles, jak selective kinase inhibitors and pharmaceutical compositions comprising them | |
| HUP0202795A2 (hu) | Pirimidin- és pirazinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| ATE104279T1 (de) | 4-fluorbenzolderivate, herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen. | |
| HUP0003332A2 (hu) | Triazolszármazékok és dopamin-D3-ligandumként való alkalmazásuk | |
| BR0212760A (pt) | Compostos quìmicos | |
| FI941987A0 (fi) | Uudet aminohappojohdannaiset, menetelmät niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset | |
| NO306464B1 (no) | Benzimidazolforbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene for fremstilling av medikamenter | |
| HUP0500870A2 (hu) | Nitrogéntartalmú heterociklusos melanokortin receptor ligandumok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AR020590A1 (es) | 7-diazapurina-n-6 sustituida, un metodo para su preparacion, composiciones farmaceuticas que la comprenden | |
| BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
| BR9608056A (pt) | Compostos de benzimidazol, composições farmacêuticas contendo os compostos e sua utilização. | |
| HUP9702509A2 (hu) | Kondenzált heterociklusos vegyületek aminocsoportjukon szubsztituált származékai, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0303480A2 (hu) | 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények | |
| CO5160242A1 (es) | UTILIZACION DE DERIVADOS DE PIRIDAZINO [4,5-b] INDOL-1- ACETAMIDA, PARA LA PREPARACION DE MEDICAMENTOS DESTINADOS A LAS ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL | |
| MY121745A (en) | 2,4-substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |